Ilex clofarabine gets user fee extension
Executive Summary
FDA extends review clock for Ilex' pediatric leukemia agent clofarabine by three months to Dec. 30 following submission of additional clinical data. Ilex completed the rolling NDA filing March 29 for priority review, originally setting a Sept. 29 user fee date. Ilex submitted data on 14 additional patients from Phase II trials in acute lymphoblastic leukemia and acute myeloid leukemia, bringing the total number of patients included in the filing to 84. Genzyme, which is seeking regulatory clearance to acquire Ilex, has conservatively projected approval for late 2005...
You may also be interested in...
Ilex Clolar Advisory Committee Splits On Pediatric Leukemia Approvals
FDA's Oncologic Drugs Advisory Committee recommended accelerated approval for Ilex' Clolar (clofarabine) in the treatment of pediatric acute lymphoblastic leukemia, but not pediatric acute myelogenous leukemia, at its Dec. 1 meeting
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.